RGCC International

27/11/2025

We’re proud to announce that RGCC presented a scientific poster at the DGHO 2025 Annual Meeting of the German, Austrian, and Swiss Societies for Hematology and Medical Oncology, held in Cologne, Germany (24–27 October 2025).

Our poster, titled “Assessment of Protein Expression and Enumeration of Circulating Tumor Cells in Various Cancer Types,” reflects RGCC’s ongoing commitment to advancing the understanding of circulating tumor cells (CTCs) and their role in cancer diagnosis, prognosis, and treatment.

With more than 6,800 participants, including physicians, scientists, and researchers, DGHO 2025 provided an exceptional opportunity for interdisciplinary collaboration and knowledge exchange, highlighting new developments in hematology and oncology.

📄 Read the full e-poster here:

Experts in developing and providing personalised cancer genetic tests for doctors and patients, RGCC is a specialist medical genetics company based in Switzerland, with laboratories worldwide.

24/11/2025

Our Oncotrace test is a powerful monitoring tool designed to assess progression. Through a simple blood draw, Oncotrace detects and analyzes circulating cells (CTCs), evaluating their presence, enumeration, and immunophenotype. This information helps determine how advanced the cancer is and the potential for metastatic spread.

By tracking CTC dynamics over time, Oncotrace enables physicians to monitor disease progression, evaluate treatment effectiveness, and make informed decisions about therapeutic strategies.

🔗 Learn more: rgcc-international.com/tests/oncotrace/

13/11/2025

As part of our ongoing commitment to corporate social responsibility, RGCC is proud to support the “Schnitte” project, run by CVJM Halle e. V., an organization dedicated to helping children living in poverty in Halle (Saale), Germany,

Through our sponsorship of the “Kinder-Hilfe-Mobil”, a newly acquired vehicle, the organization can continue to deliver essential services such as:

🚐 Regular food deliveries and meal support
🚐 Transportation to schools and kindergartens
🚐 Excursions and leisure activities for children
🚐 Collection and distribution of donated goods and food

RGCC will sponsor this project for the next five years, contributing to the continued operation and outreach of this meaningful community initiative.

Last week, we were honored to take part in the ceremonial handover in Halle (Salle), represented by our colleague Sabine Klatt.

At RGCC, we remain committed to supporting initiatives that foster care and well-being within our communities.

11/11/2025

🎥 Prof. Georgia Gioula, Professor of Medical Microbiology and Virology, explains how ’s InVyomma Plus test provides clinicians with powerful insights to guide personalized treatment plans.

InVyomma Plus integrates next-generation sequencing and advanced bioinformatics to map how microbes interact with the human body, while also measuring short-chain fatty acids in stool samples for a deeper look at bacterial balance and activity.

The result? Actionable data that helps physicians make more informed, targeted therapeutic decisions.

👉 Learn more about InVyomma Plus and RGCC’s full range of diagnostic tests: rgcc-international.com/tests/

06/11/2025

In a recent study, Statistician George Beis and our Director, Dr. Ioannis Papasotiriou, explored how different statistical tests perform when the proportional hazards (PH) assumption doesn’t hold in immuno-oncology trials.

Their findings show that while methods like weighted log-rank (GW), MK-S, and NY1/NY2 tests can better detect early or delayed treatment effects, no single test fits all scenarios. The authors recommend using a combination of robust, data-driven approaches to ensure accuracy and transparency in survival analyses.

📊 You can find all our published studies here:

Experts in developing and providing personalised cancer genetic tests for doctors and patients, RGCC is a specialist medical genetics company based in Switzerland, with laboratories worldwide.

03/11/2025

Join us this as we shine a light on men’s health. From prostate and testicular cancer to mental health, men’s wellbeing matters.

At , we’re committed to transforming cancer care through precision diagnostics with a special focus on early detection that saves lives.

Let’s continue the conversation this Movember and support research that truly changes lives. Learn more about Movember here: https://ch.movember.com/en/?home

29/10/2025

🎥 Hear it from the experts!
Oncologists and healthcare professionals share why they trust RGCC testing to deliver accurate insights and guide personalized treatment for their patients.

📚 Explore our diagnostic tests and their clinical applications: rgcc-international.com

23/10/2025

At , we believe early detection and personalized testing can change the course of someone’s health journey.

B.T.’s story is a powerful reminder of how proactive choices and precision can lead to life-saving insights.

🌱 Explore more patient experiences: rgcc-international.com/testimonials/

20/10/2025

Through tailored tests, we aim to empower people facing cancer with tailored insights that can change the course of their journey. The aim of our cancer blood tests is to detect, analyze, and examine cells early at every stage of the disease.

Our minimally invasive liquid biopsy tests offer promising opportunities for early cancer detection and treatment. In this process, the focus is always on providing clinicians and patients with a clinical basis on which they can make well-founded and personalized decisions for individual cancer treatment.

Learn more > rgcc-international.com/tests/

15/10/2025

Watch as surgical oncologists Dr. Sonar Soni Panigoro and Dr. Walta Guatama share how RGCC’s Liquid Biopsy tests, including Oncotrace, are redefining how oncologists monitor cancer, offering patients a less invasive alternative to traditional biopsies.

09/10/2025

The biology of a cancerous tumor works similarly to skin or hair. Just like the body sheds hair and skin cells, the tumor sheds cells throughout its lifespan. These cells are called circulating tumor cells (CTCs), and they can be detected in the bloodstream. Therefore, when a blood sample is analyzed for diagnosis, the test will measure the presence of CTCs.

At , we use liquid biopsies to measure the CTC count. A liquid biopsy is a non-invasive way to measure cancer in the body by measuring the number of CTCs in the bloodstream.

The detection and monitoring of markers circulating in the blood are useful for the prognosis and prediction of a patient’s response to therapy.

Explore our full range of CTC tests for cancer screening and monitoring: https://rgcc-international.com/tests/

06/10/2025

Our team presented the poster: “Cell fusion model to investigate a potential origin of circulating cells.”

The study explores the cell fusion process, the merging of the membranes of two or more cells into one hybrid cell, which is associated with cancer initiation, progression, and metastasis. It particularly focuses on the fusion of and immune cells, which can create hybrid cells with unique properties, including drug resistance, immune evasion, and cancer progression. Therefore, the project aimed to establish an in vitro cell fusion model to investigate this important biological process.

📄 Explore the full poster and our published research: rgcc-international.com/published-articles/

📸 See highlights from the event below.